**Original Article**

**Association of adiponectin and metabolic syndrome in women**

*Mojgan Sanjari,1 Mandana Khodashahi,2 Ahmad Gholamhoseinian,3 Mostafa Shokoohi4*

**Abstract**

**BACKGROUND:** An inverse association between serum adiponectin level and metabolic syndrome was seen in few studies. The aim of this study was to assess the association between serum adiponectin levels and metabolic syndrome in a sample of Iranian women from Kerman.

**METHODS:** In a cross-sectional study 946 subjects were studied to determine the prevalence of metabolic syndrome and in a case control study (170 subjects for each group) the association between serum adiponectin levels and metabolic syndrome were investigated. Metabolic syndrome was defined using International Diabetes Federation (IDF) criteria. Socio-demographics factors and measures of waist circumference, blood pressure and lipid profiles were collected. Serum adiponectin level was measured by ELISA method.

**RESULTS:** The prevalence of the metabolic syndrome was 36.7%. Mean of serum adiponectin level in individuals with metabolic syndrome was lower than individuals without it (10.5 ± 4.1 and 13.45 ± 5.6 µg/ml, respectively, p < 0.001). Low level of adiponectin was a good predictor for metabolic syndrome (a range of β coefficients out of -2.03 to -2.85 according to five models). Systolic blood pressure, body mass index (BMI) and diastolic blood pressure were independent predictors of serum adiponectin (p values were 0.001, 0.009 and 0.034, respectively).

**CONCLUSIONS:** We found that adiponectin is negatively associated with metabolic syndrome. Systolic and diastolic blood pressure and BMI were identified as independent predictors.

**KEYWORDS:** Metabolic Syndrome, Adiponectin, Body Mass Index, Blood Pressure, Women.
cytokine-derived hormone adiponectin may be a predictor factor for metabolic syndrome. Higher serum adiponectin levels are associated with decreased risk for development of obesity, type 2 diabetes, insulin resistance, dyslipidemia and CVD. Adiponectin levels are varied according to some factors such as sex, age, race and ethnicity. Evidences have proposed that there is a relation between serum adiponectin and metabolic syndrome in different ethnic groups such as whites, Asian Indians, Koreans and Japanese. However, there have not been further studies conducted on serum adiponectin levels and its association with some complications particularly metabolic syndrome in Iran.

According to some studies, the prevalence of metabolic syndrome is high in Iran. Azizi et al. in 2003 showed that the prevalence of metabolic syndrome was more than 30% in adults, which it was more prevalent in women than men (42% vs. 24%). Zabetian et al. in 2007 revealed a 40% age-adjusted prevalence of metabolic syndrome in urban Tehranian women (≥20 years old). This prevalence in Delavar et al. study in 2009 was approximately 30%, and in Gharipour et al. study in 2006 among 50-59 years old female rural residences in Isfahan was approximately 70%. These studies have highlighted the importance of the study on metabolic syndrome in Iranian population. Ethnicity plays key role in the association of adiponectin levels and metabolic syndrome. However, little is known regarding the role of adiponectin on metabolic syndrome in Iranian population. The present study was aimed to assess the prevalence of metabolic syndrome and the association between serum adiponectin levels and metabolic syndrome among women in Kerman, Iran.

Methods
Participants:
This study was done in 2009 and was conducted in two steps. The first step was done to determine the prevalence of metabolic syndrome based on a cross-sectional study design. There was a Women Health Committee in Kerman Province which evaluates cardiovascular risk factors and screens breast cancer in these women. In this step a number of 946 women aged 25-53 years were selected randomly. This study was approved by ethical committee of Kerman University of Medical Sciences (KUMS). The importance of this study and metabolic syndrome was described for all participants. An informed written consent was obtained from all participants in the study.

After determining the prevalence of metabolic syndrome according to International Diabetes Federation (IDF) criteria, to determine the association of serum adiponectin levels and metabolic syndrome, 170 subjects were randomly selected from two groups with and without metabolic syndrome (totally, 340 subjects were recruited). Women with Cushing disease or its clinical signs, secondary obesity, hypothyroidism, disabling diseases, cancer and also pregnant and nursing women were excluded.

Definition of the Metabolic Syndrome:
Metabolic syndrome was defined according to IDF criteria in this definition, unlike World Health Organization (WHO) and National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III) criteria, waist circumference (WC) as indicates central obesity, is an essential component for metabolic syndrome. WC shall be obtained by ethnic- and sex-specific cut-off point. In IDF consensus for Caucasian people, this cut-off point was ≥ 94 cm for men and ≥ 80 cm for women. Along with WC, the presence of at least two of the following abnormalities comprised the metabolic syndrome:
1. Triglycerides level ≥ 150 mg/dl, or drug or specific treatment for this abnormality
2. HDL cholesterol < 40 mg/dl, or drug or specific treatment for this abnormality
3. Fasting plasma glucose (FPG) ≥ 100 mg/dl, or previously diagnosed type 2 diabetes, or drug or specific treatment for this conditions
4. Blood pressure ≥ 130/85 mmHg, or previously diagnosed hypertension or specific treatment for this abnormality
Data collection:
A questionnaire to collect some information such as age and etc. was completed for all participants. Weight was measured to the nearest 0.1 kg with a calibrated physician’s office scale and height was measured to the nearest 1 mm with a tape meter. Body mass index (BMI) was a number calculated by dividing the body weight (in kilograms) by the height squared (in meters). Waist Circumference was measured using an unstretched tape meter, located directly on the skin while the subject stood balanced with legs parallel, and was recorded to the nearest 0.1 cm. To minimize errors, all measurements were performed by one nurse. To measure blood pressure, systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured by a trainee nurse twice in a seated position. There was at least a 30 min interval between these two measurements, and then the mean of the two measurements was set as blood pressure of participants.

Laboratory measurements:
A blood sample (10 ml) was taken out of left brachial vein of these participants and FPG was measured by enzymatic colorimetric method using glucose oxidase (Pars Azmoon Inc. Iran). For lipid profiles, total cholesterol and triglyceride (TG) kits (Pars Azmoon Inc., Iran) were used. Total cholesterol (TC) and TG were analyzed using enzymatic colorimetric tests with cholesterol esterase and cholesterol oxidase, respectively. HDL-C was measured after precipitation of the apolipoprotein β containing lipoproteins with Phosphotungstic acid. Low-Density Lipoprotein (LDL) concentration was indirectly calculated as the Friedewald formula: LDL=TC-HDL- (TG/5).37

Participations with and without metabolic syndrome were distinguished on the basis of IDF (2005) criteria and case and control groups were selected accordingly. Five milliliter of blood sample was taken from brachial vein of both two groups in order to determine serum adiponectin levels at 8 Am. Serum was separated and kept in -70°C and adiponectin concentration was measured by ELISA method (DIASORIN Inc. kit).38

Statistical Analysis:
Data were presented as mean ± standard deviation (SD) for continuous variables and absolute and relative frequency for categorical variables. Two groups of participants with and without metabolic syndrome were compared using Student’s t-test. Univariate and multivariate (to adjust the potential confounders such as age, BMI and each components of metabolic syndrome) linear regression were used to determine the association between metabolic syndrome and adiponectin. Beta coefficients (β) with standard errors (S.E.) and coefficient of determination (R²) were presented. Multivariate forward stepwise linear regression analysis was used to determine the independent predictors’ variables affecting serum adiponectin level. All statistical analyses were performed using SPSS version 15 statistical software package (SPSS Inc. Chicago, IL). P value less than 0.05 was considered as statistically significant.

Results
The prevalence of metabolic syndrome according IDF criteria was 36.7%. Baseline and clinical characteristics of women with and without metabolic syndrome are presented in table 1. Participants with metabolic syndrome had higher age, BMI, waist and hip circumferences and waist to hip ratio (p < 0.001), lower systolic and diastolic blood pressure (p < 0.001), higher FPG, cholesterol, triglyceride and LDL (p < 0.001). There was a highly significant difference in adiponectin level between the two groups. Adiponectin level in women with metabolic syndrome was lower than that in those without metabolic syndrome (10.5 ± 4.1 vs. 13.45 ± 5.6 µg/ml, p < 0.001).

Univariate linear regression analysis of serum adiponectin level in women with metabolic syndrome is presented in table 2. Waist to hip ratio (β = -8.80, p = 0.039) and triglyceride (β = -0.014, p < 0.001) were negatively
Adiponectin and metabolic syndrome

Table 1. Clinical and baseline characteristics of metabolic and non metabolic syndrome

| Characteristics               | Participants with Metabolic Syndrome (n=170) | Participants without Metabolic Syndrome (n=170) | P value |
|------------------------------|---------------------------------------------|-----------------------------------------------|---------|
| Age (year)                   | 38.5 ± 6.3 *                              | 34.02 ± 5.8                                   | < 0.001 |
| Body Mass Index (kg/m²)      | 29.1 ± 4.7                                 | 26.9 ± 4.8                                    | 0.57    |
| Waist Circumference (cm)     | 101.8 ± 12.5                               | 84.9 ± 8.6                                    | 0.041   |
| Hip Circumference (cm)       | 109.4 ± 13.3                               | 94.8 ± 12.1                                   | 0.045   |
| Waist to Hip Ratio           | 0.93 ± 0.05                                | 0.90 ± 0.07                                   | < 0.001 |
| Adiponectin (µg/ml)          | 10.5 ± 4.1                                 | 13.45 ± 5.6                                   | 0.68    |
| Systolic Blood Pressure (mmHg)| 11.1 ± 0.92                                | 11.6 ± 0.91                                   | < 0.001 |
| Diastolic Blood Pressure (mmHg)| 6.8 ± 0.97                              | 7.2 ± 0.88                                     | < 0.001 |
| Fasting Plasma Glucose (mg/dl)| 102.2 ± 29.5                              | 92.3 ± 16.1                                   | < 0.001 |
| Total Cholesterol (mg/dl)    | 215.6 ± 42.7                               | 187.7 ± 45.1                                  | < 0.001 |
| Triglyceride (mg/dl)         | 219.6 ± 81.1                               | 123.5 ± 69.5                                  | < 0.001 |
| High-Density Lipoprotein (mg/dl)| 42.2 ± 20.3                             | 46.9 ± 31.8                                    | 0.06    |
| Low-Density Lipoprotein (mg/dl)| 137.4 ± 37.9                             | 117.01 ± 35.1                                 | < 0.001 |

* Mean ± standard deviation

correlated with serum adiponectin level, while FPG (β = 0.025, p = 0.033) was positively correlated with serum adiponectin level. BMI had a borderline negative correlation with adiponectin in cases with metabolic syndrome (β = -0.13, p = 0.056).

Multivariate linear regression analysis is presented in table 3. In the unadjusted model, adiponectin was negatively associated with metabolic syndrome (β = -2.85, p < 0.001). In the model adjusted by BMI and waist to hip ratio, the result was similar (β = -2.11, p = 0.008). The model adjusted by FPG, TG, TC, HDL and LDL, SBP and DBP also produced similar results as unadjusted model (β = -2.26, p = 0.001). When the variables in models 2 and 3 were adjusted with age, the result was similar (β = -2.037, p = 0.038).

Table 2. Univariate linear regression analysis of serum adiponectin with baseline and clinical variables

| Variables                        | β_Crude | S.E | R² | P value   |
|----------------------------------|---------|-----|----|-----------|
| Metabolic Syndrome (yes)         | -2.85   | 0.55| 0.076| < 0.001*  |
| Age                              | -0.005  | 0.045| 0.001| 0.91      |
| Waist Circumference              | -0.33   | 0.02 | 0.008| 0.11      |
| Body Mass Index                  | -0.13   | 0.07 | 0.017| 0.056     |
| Hip Circumference                | 0.008   | 0.02 | 0.001| 0.66      |
| Waist to Hip Ratio               | -8.80   | 4.5 | 0.013| 0.039*    |
| Systolic Blood Pressure (mmHg)   | 0.23    | 0.28 | 0.002| 0.41      |
| Diastolic Blood Pressure (mmHg)  | 0.45    | 0.31 | 0.007| 0.13      |
| Blood Pressure (> 140/85)        | 0.78    | 0.89 | 0.002| 0.43      |
| Fasting Plasma Glucose           | 0.025   | 0.012| 0.014| 0.033*    |
| Total Cholesterol                | 0.001   | 0.006| 0.001| 0.85      |
| Triglyceride                     | -0.014  | 0.003| 0.065| < 0.001*  |
| High-Density Lipoprotein         | -0.008  | 0.011| 0.002| 0.42      |
| Low-Density Lipoprotein          | 0.005   | 0.007| 0.002| 0.46      |

J Res Med Sci / December 2011; Vol 16, No 12.
Table 3. Multivariate linear regression analysis of baseline and clinical characteristics in 4 adjusted models

| Linear regression models                                      | β    | R²   | P value |
|--------------------------------------------------------------|------|------|---------|
| Model 1 (unadjusted, only metabolic syndrome)                | -2.85| 0.076| < 0.001 |
| Model 2 (metabolic syndrome, adjusted for BMI and waist to hip ratio) | -2.11| 0.079| 0.008   |
| Model 3 (metabolic syndrome, adjusted for FPG, TG, TC, HDL, LDL, SBP, and DBP) | -2.26| 0.118| 0.001   |
| Model 4 (metabolic syndrome, adjusted for age and variables in models 2 and 3) | -2.037| 0.177| 0.038   |

BMI: Body Mass Index, FPG: Fasting Plasma Glucose, TG: Triglyceride, TC: Total Cholesterol, HDL: High-Density Lipoprotein, LDL: Low-Density Lipoprotein, DBP: Systolic Blood Pressure, SBP: Systolic Blood Pressure

Multivariate forward stepwise linear regression analysis of the variables showed that systolic blood pressure (β = -1.36, p = 0.001), BMI (β = -0.18, p = 0.009) and diastolic blood pressure (β = 0.92, p = 0.034) were independent predictors of serum adiponectin level and explained approximately 41.4% of the whole variance (Table 4).

Discussion

The results of the present study showed that the prevalence of metabolic syndrome based on IDF definition in women employees in Kerman was approximately 37%. Serum adiponectin levels of subjects with and without metabolic syndrome were completely different in both univariate and multivariate models. Women with metabolic syndrome had lower serum adiponectin, which it was statistically significant Systolic and diastolic blood pressure and also BMI were identified as independent predictors for serum adiponectin level.

Prevalence of metabolic syndrome in our study was more than what had been reported in developed countries such as U.S, America, Illinois province, Europe, Chinese adults and Korean adults that were varied from 15% to 25%. However, a study by Ervin in U.S (2009) recently showed that the prevalence of metabolic syndrome was approximately 35%. This finding was similar to our study and the other studies in developing countries. Our findings was also in line with the findings of studies which showed higher prevalence of metabolic syndrome in Middle East countries rather than other countries specially Europe. According to IDF definition, the prevalence of metabolic syndrome in the present study also was so close to Tehran Lipid and Glucose Study (TLGS) which it was 30% in total of men and women participants.

Our study revealed that in most participants with metabolic syndrome, there was significant relationship between metabolic syndrome and serum adiponectin level. There is a consistency with the results of recent studies that have studied low serum adiponectin levels in participants with metabolic syndrome. Wang et al. in a study in China showed that the participants in the lowest adiponectin

Table 4. Multivariate forward stepwise linear regression analysis of baseline and clinical characteristics: correlation to serum adiponectin level among cases with metabolic and non-metabolic syndrome

| Linear regression models       | β    | R²   | P value |
|--------------------------------|------|------|---------|
| Metabolic syndrome             | -2.33| 0.064| 0.001   |
| Systolic Blood Pressure        | -1.36| 0.111| 0.001   |
| Body Mass Index                | -0.18| 0.164| 0.009   |
| Diastolic Blood Pressure       | 0.92 | 0.139| 0.034   |
quartile had a significant increased risk for obtaining metabolic syndrome (Odds ratio was 3.38 for lowest adiponectin quartile vs. highest adiponectin quartile). 49

In a case study, Kumagai et al. 50 showed that level of serum adiponectin decreases in people with metabolic syndrome, and adiponectin to serum leptin ratio can be a suitable marker for determining the prevalence of metabolic syndrome. In another study, after adjusting the age and sex variables, it was shown that concentration of serum adiponectin had a reverse relationship with BMI, waist to hip circumference ratio, diastolic blood pressure, triglyceride, glucose and fasting insulin, and a direct relationship with HDL level; in people with the lowest adiponectin level, metabolic syndrome increased significantly. 51 In our study, lower serum adiponectin was associated with higher systolic blood pressure and BMI but lower diastolic blood pressure.

The results of one of these studies showed that increased level of circulating adiponectin in blood inhibits the prevalence of inflammations related to lipid tissue, insulin resistance and metabolic syndrome in obese people. 52 In a study carried out on Caucasian people aged 8-19 years, it was shown that people with metabolic syndrome may experience high levels of visceral fat, fasting insulin, low sensitivity to insulin and low level of adiponectin. In these people, level of inflammatory biomarkers was high too. 53 Performing a study in the same field, Tabara et al. revealed that adiponectin concentration with high molecular weight (HMW adiponectin) decreased significantly in plasma with regards to all elements of metabolic syndrome except for high blood pressure. 54 In the present study a significant negative association was found between serum adiponectin and metabolic syndrome. Our study showed a negative association between adiponectin and systolic blood pressure and BMI and a positive correlation with diastolic blood pressure. Patients with hypertension appear to have significantly lower plasma adiponectin levels than normotensive patients, 55 but there has been no difference in adiponectin level between patients with and without CVD. While CVD was significantly associated with hypertension and this association was stronger in men than in women, this effect was more significant than the effect of other elements of metabolic syndrome such as LDL cholesterol and diabetes. 56 In this study, the correlation between blood pressure and adiponectin level was not mentioned.

One of the limitations of our study was that the sample size was low and limited to female employees. Another limitation of our study was that its cross-sectional design which is not an appropriate design for examination of the relationship between adiponectin as a causing factor and metabolic syndrome.

As the major importance of metabolic syndrome is its contribution to CVD and as our study showed the effect of BP on adiponectin, it is recommended to pay more attention to the effect of blood pressure on adiponectin level and CVD.

Acknowledgment

This research was a Resident’s thesis that supported by Kerman Physiology Research Center and Vice Chancellor for research, Kerman University of Medical Sciences (research project number was 87/136). Authors would like to acknowledge all women who participated in this study, and also thank to Dr. Mahdieh Mashrooteh and Ms. Tahereh Lashkari for assistance in this research.

Conflict of Interests

Authors have no conflict of interests.

J Res Med Sci / December 2011; Vol 16, No 12. 1537
Authors' Contributions
Study design: MSa, MK; data analysis: MSh; literature review: MSa, MSh, MK; laboratory test: AG; Manuscript preparation: MSa, MSh.

References
1. Kim MH, Kim MK, Choi BY, Shin YJ. Prevalence of the metabolic syndrome and its association with cardiovascular diseases in Korea. J Korean Med Sci 2004; 19(2): 195-201.
2. Conus F, Allison DB, Rabasa-Lhoret R, St-Onge M, St-Pierre DH, Tremblay-Lebeau A, et al. Metabolic and behavioral characteristics of metabolically obese but normal-weight women. J Clin Endocrinol Metab 2004; 89(10): 5013-20.
3. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365(9468): 1415-28.
4. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24(4): 683-9.
5. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288(21): 2709-16.
6. Mohammadzadeh G, Zarghami N. Hypoadiponectinemia in obese subjects with type II diabetes: A close association with central obesity indices. J Res Med Sci 2011; 16(6): 713-23.
7. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287(3): 356-9.
8. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care 2004; 27(10): 2444-9.
9. Azizi F, Rahmanian M, Ghanbarian A, Emami H, Salehi P, Mirmiran P, et al. Serum lipid levels in an Iranian adults population: Tehran Lipid and Glucose Study. Eur J Epidemiol 2003; 18(4): 311-9.
10. Zabetan A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATPIII and the WHO definitions. Diabetes Res Clin Pract 2007; 77(2): 251-7.
11. Delavar MA, Lye MS, Khor GL, Hanachi P, Hassan ST. Prevalence of metabolic syndrome among middle aged women in Babol, Iran. Southeast Asian J Trop Med Public Health 2009; 40(3): 612-28.
12. Gharpour M, Kelishadi R, Baghaie M, Boshtam M, Rabeie K. Prevalence of metabolic syndrome in an Iranian adult population. ARYA Journal 2006; 1(3): 188-92.
13. Vasseur F, Adiponectin and its receptors: partners contributing to the "vicious circle" leading to the metabolic syndrome? Pharmacol Res 2006; 53(6): 478-81.
14. Chandran M, Phillips SA, Ciardaldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care 2003; 26(8): 2442-50.
15. Mojiminiyi OA, Abdella NA, Al AM, Ben NA. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes. Int J Obes (Lond) 2007; 31(2): 213-20.
16. Yoon SJ, Lee HS, Lee SW, Yun JE, Kim SY, Cho ER, et al. The association between adiponectin and diabetes in the Korean population. Metabolism 2008; 57(6): 853-7.
17. Jalovaara K, Santaniemi M, Timonen M, Jokelainen J, Kesaniemi YA, Ukkola O, et al. Low serum adiponectin level as a predictor of impaired glucose regulation and type 2 diabetes mellitus in a middle-aged Finnish population. Metabolism 2008; 57(8): 1130-4.
18. Sheng T, Yang K. Adiponectin and its association with insulin resistance and type 2 diabetes. J Genet Genomics 2008; 35(6): 321-6.
19. Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 2007; 92(2): 571-6.
20. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006; 114(7): 623-9.
21. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocytely-derived protein. Diabetes 2002; 51(9): 2734-41.
22. Adamczak M, Rzepka E, Chudek J, Wieczek A. Ageing and plasma adiponectin concentration in apparently healthy males and females. Clin Endocrinol (Oxf) 2005; 62(1): 114-8.
23. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86(5): 1930-5.
24. Ervin RB. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report 2009; (13): 1-7.
25. Gilardini L, McMarn PG, Girola A, da Silva NF, Alberti L, Kumar S, et al. Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents. Atherosclerosis 2006; 189(2): 401-7.
26. Mohan V, Deepa R, Pradeepa R, Vimalaswaran KS, Mohan A, Velmurugan K, et al. Association of low adiponectin levels with the metabolic syndrome—the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism 2005; 54(4): 476-81.
27. Kim SM, Cho KH, Park HS. Relationship between plasma adiponectin levels and the metabolic syndrome among Korean people. Endocr J 2006; 53(2): 247-54.
28. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68(11): 975-81.
29. Shojaei M, Sotoodah A, Shafaei G. Is adiponectin associated with acute myocardial infarction in Iranian non obese patients? Lipids Health Dis 2009; 8: 17.
30. Giahi L, Djazayery A, Rahimi A, Rahmany M, Larijani B. Serum level of adiponectin and its association with insulin sensitivity in overweight diabetic and non-diabetic Iranian men. Iranian J Publ Health 2008; 37(2): 88-92.
31. Mohebbi H, Moghadasi M, Rahman-Nia F, Hassan-Nia S, Noroozi H. Association among lifestyle status, plasma adiponectin level and metabolic syndrome in obese middle aged men. Brazilian Journal of Biometry 2009; 3(3): 243-52.
32. Tabatabaei-Malazy O, Hasani-Ranjbar S, Amoli MM, Heshmat R, Sajadi M, Derakhshan R, et al. Gender-specific differences in the association of adiponectin gene polymorphisms with body mass index. Rev Diabet Stud 2010; 7(3): 241-6.
33. Hajmohammadi T, Sadeghi M, Dashti M, Hashemi M, Saadatnia M, Soghri M, et al. Relationship between carotid intima-media thickness with some inflammatory biomarkers, ghrelin and adiponectin in Iranians with and without metabolic syndrome in Isfahan cohort study. ARYA J 2010; 6(2): 56-61.
34. International Diabetes Federation Press Conference. The IDF consensus worldwide definition of the metabolic syndrome [Online] 2005; [cited 2005 Apr 14]. Available from: URL: http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf.
35. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15(7): 539-53.
36. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.
37. Rifai N, Warnick GR. Measurement of lipids, lipoproteins, and apolipoproteins. In: Burtis CA, Ashwood ER, Bruns DE, editors. Tietz Textbook of Clinical Chemistry and Molecular Diagnosis. 4th ed. Philadelphia: Saunders; 2005. p. 938-52.
38. Wang CH, Wang JH, Lee CJ, Fang TC, Liou HH, Hsu BG. Fasting serum adiponectin level inversely correlates with metabolic syndrome in peripheral dialysis patients. Blood Purif 2010; 30(1): 1-7.
39. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation 2003; 108(13): 1546-51.
40. Reppert A, Steiner BF, Chapman-Novakofski K. Prevalence of metabolic syndrome and associated risk factors in Illinois. Am J Health Promot 2008; 23(2): 130-8.
41. Villegas R, Perry LJ, Creagh D, Hinchion R, O’Halloran D. Prevalence of the metabolic syndrome in middle-aged men and women. Diabetes Care 2003; 26(11): 3198-9.
42. Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005; 365(9468): 1398-405.
43. Li Y, Yang X, Zhai F, Kok FJ, Zhao W, Piao J, et al. Prevalence of the metabolic syndrome in Chinese adolescents. Br J Nutr 2008; 99(3): 565-70.
44. Park HS, Lee SY, Kim SM, Han JH, Kim DJ. Prevalence of the metabolic syndrome among Korean adults according to the criteria of the International Diabetes Federation. Diabetes Care 2006; 29(4): 933-4.
45. Mirmiran P, Sherafat-Kazemzadeh R, Farahani SJ, Asghari G, Niroomand M, Momenan A, et al. Performance of different definitions of metabolic syndrome for children and adolescents in a 6-year follow-up: Tehran Lipid and Glucose Study (TLGS). Diabetes Res Clin Pract 2010; 89(3): 327-33.
46. Fischer CP, Perstrup LB, Bernsen A, Eskildsen P, Pedersen BK. Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clin Immunol 2005; 117(2): 152-60.
47. You T, Ryan AS, Nicklas BJ. The metabolic syndrome in obese postmenopausal women: relationship to body composition, visceral fat, and inflammation. J Clin Endocrinol Metab 2004; 89(11): 5517-22.
48. Salmenniemi U, Ruotsalainen E, Pihlajamäki J, Vauhkonen I, Kainulainen S, Punnonen K, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 2004; 110(25): 3842-8.

49. Wang J, Li H, Franco OH, Yu Z, Liu Y, Lin X. Adiponectin and metabolic syndrome in middle-aged and elderly Chinese. Obesity (Silver Spring) 2008; 16(1): 172-8.

50. Kumagai S, Kishimoto H, Masatakasuwa, Zou B, Harukasasaki. The leptin to adiponectin ratio is a good biomarker for the prevalence of metabolic syndrome, dependent on visceral fat accumulation and endurance fitness in obese patients with diabetes mellitus. Metab Syndr Relat Disord 2005; 3(2): 85-94.

51. Maynadier M, Basile I, Gary-Bobo M. Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant. Drug Discov Today 2009; 14(3-4): 192-7.

52. Hung J, McQuillan BM, Thompson PL, Beilby JP. Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes (Lond) 2008; 32(5): 772-9.

53. Lee S, Bacha F, Gungor N, Arslanian S. Comparison of different definitions of pediatric metabolic syndrome: relation to abdominal adiposity, insulin resistance, adiponectin, and inflammatory biomarkers. J Pediatr 2008; 152(2): 177-84.

54. Tabara Y, Osawa H, Kawamoto R, Tachibana-Iimori R, Yamamoto M, Nakura J, et al. Reduced high-molecular-weight adiponectin and elevated high-sensitivity C-reactive protein are synergistic risk factors for metabolic syndrome in a large-scale middle-aged to elderly population: the Shimanami Health Promoting Program Study. J Clin Endocrinol Metab 2008; 93(3): 715-22.

55. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003; 16(1): 72-5.

56. Mitsutake R, Miura S, Shiga Y, Uehara Y, Saku K. Association between hypertension and coronary artery disease as assessed by coronary computed tomography. J Clin Hypertens (Greenwich ) 2011; 13(3): 198-204.